However, to date, no study has revealed the p53‐independent carcinogenic activity of FAM175B in ESCC patients, among which almost 70% exhibit p53 mutation (Abedi‐Ardekani, 2014; Kawano et al., 2014; Makino et al., 2010). Here, ABRAXAS2 is linked to esophageal squamous cell carcinoma.